A Goa-based company you've probably never heard of might have swabbed your nose during the pandemic.
Now it's coming to the stock market.
Molbio Diagnostics has fixed its IPO price band at ₹768 to ₹807 per share, and the numbers are about to get real for retail investors.
Subscription opens August 10, closes August 12, and if you're in, you're in for the long haul — allotment on August 13, refunds and demat credit on August 14, and listing on the BSE and NSE on August 17.
The minimum bet: one lot of 18 shares, which works out to roughly ₹14,500 at the upper band.
So who is Molbio, and why should you care?
Molbio didn't just make COVID test kits.
It built something bigger — a portable, battery-operated PCR machine called Truenat, small enough to sit on a table in a rural clinic, that spits out molecular diagnostic results in under an hour.
No fancy lab. No days of waiting.
That's a genuinely big deal in a country where the nearest proper diagnostic lab can be hours away.
Today, Truenat tests for more than 30 diseases across 43 different assays — tuberculosis, COVID-19, HIV, Hepatitis B and C, HPV, and more.
Founded in 2000, this is not a pandemic-born startup chasing a moment. It's a two-decade-old diagnostics company that happened to be in the right place when the world needed rapid testing most.
Here's the structure of the issue:
And the fresh issue money isn't just sitting idle. It's earmarked:
The promoters — Exxora Trading and Dr Chandrasekhar Bhaskaran Nair — currently hold 46.65% of the company.
The remaining 53.35% sits with a cast of serious institutional names, including a subsidiary of Temasek Holdings and the Motilal Oswal Group-backed India Business Excellence Fund.
Both of those investors, along with seven other shareholders, are among those selling down stakes in the OFS.
Worth noting: this isn't a founder cashing out and walking away. The promoters are only partially diluting, and the company got SEBI's green light back in December 2025 — so this has been in the works for a while.
That's a heavyweight banking syndicate for a company most household investors are only just discovering.
India's diagnostics space has been quietly consolidating attention from investors — decentralised, point-of-care testing is exactly the kind of infrastructure play that scales fast in a country still underserved by traditional labs.
Molbio isn't chasing a single blockbuster drug or a hype cycle.
It's selling picks and shovels for disease detection — in villages, in district hospitals, in places big diagnostic chains haven't bothered to reach.
Whether the stock pops on listing day is anyone's guess.
But the story underneath it — a homegrown molecular diagnostics company that helped India test its way through a pandemic, now asking public markets to fund its next chapter — is one worth understanding before the bell rings on August 17.
That's all for now!
